Clinical trials: Primary Sjögren's Syndrome (pSS)
Primary Sjögren's Syndrome (pSS)
A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome
This project aims to conduct a prospective, randomized, double-blind, controlled clinical study to clarify the efficacy and safety of the YiQi YangYin Formula in treating patients with primary Sjogren's syndrome (pSS) presenting…
- Trial name
- NCT07145060
- Testing
- Yiqi Yangyin Formula
- Where
- China
- Volunteers
- 105 people
- Sponsor
- China-Japan Friendship Hospital
Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants…
- Trial name
- NCT07751315
- Testing
- Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Autoimmune Diseases
A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
This is a pilot imaging study to determine whether molecular imaging with 18^F fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 11^C-Methionine (MET) PET/CT, and salivary gland magnetic…
- Trial name
- NCT02899377
- Testing
- 18F-FDG PET/CT Imaging, 11C-MET PET/CT Imaging, MRI Imaging with intravenous contrast with gadoterate meglumine
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sjogren's Syndrome
Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)
Sjogren's Syndrome is a chronic autoimmune disease characterized by sicca (dryness) symptoms of the mouth and eyes. This autoimmune disease is less commonly studied and there are no licensed treatments to treat the underlying…
- Trial name
- NCT03501420
- Testing
- Interview, PSC questionnaire, PRFs
- Where
- United Kingdom
- Volunteers
- 2,223 people
- Sponsor
- GlaxoSmithKline
Sjogren's Syndrome, Mesenchymal Stem Cells
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
This study will explore safety and efficacy of allogeneic mesenchymal stem cells transplantation (MSCT) to treat patients with diagnosis of primary Sjögren's Syndrome (pSS) who have been resistant to multiple standard treatments.
- Trial name
- NCT00953485
- Testing
- Allogeneic Mesenchymal Stem Cells (AlloMSC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Primary Sjögren's Syndrome (pSS)
Artificial Intelligence Based Models for Primary Sjögren's Syndrome Diagnosis
The goal of this observational study is to develop and validate artificial intelligence (AI)-driven models for improving the diagnosis of Primary Sjögren's Syndrome (PSS) using routine laboratory test data.
- Trial name
- NCT06982482
- Where
- China
- Volunteers
- 27,432 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Primary Sjögren's Syndrome (pSS)
Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort
This study aims to evaluate the diagnosis performance of several item used for the classification, the diagnosis and the prognostic of pSS (primary Sjogren syndrome)
- Trial name
- DIApSS (NCT03681964)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of QLS2416 injection in participants with autoimmune diseases (AID).
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc)
- Trial name
- NCT07906145
- Testing
- QLS2416 Injection
- Volunteers
- 76 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
This study aims to evaluate the safety, tolerability and PK of repeat dose administration of GSK2618960 in the treatment of pSS.
- Trial name
- NCT03239600
- Testing
- GSK2618960 2 mg/kg, Methotrexate
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Primary Sjögren Syndrome
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).
- Trial name
- NCT04093531
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Primary Sjögren's Syndrome (pSS)
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjögren's Syndrome.
- Trial name
- NCT06862284
- Testing
- Upadacitinib (ABT-494), Hydroxychloroquine (HCQ)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Primary Sjögren's Syndrome
A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.
- Trial name
- rho (NCT05817669)
- Testing
- Efgartigimod
- Where
- 17 sites in Belgium, Hungary and 2 more
- Volunteers
- 34 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS).
- Trial name
- Rho plus (NCT06203457)
- Testing
- Efgartigimod
- Where
- 11 sites in Belgium, Hungary and 1 more
- Volunteers
- 24 people
- Sponsor
- argenx
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sjögren's Syndrome (pSS)
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab.
- Trial name
- NCT07852234
- Testing
- Blinatumomab, background treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tongren Hospital
Primary Sjögren's Syndrome (pSS)
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome
This is a phase2a, multicenter, double-blind, placebo control, randomized study to investigate the efficacy and safety of SA001 in subjects with pSS.
- Trial name
- NCT05269810
- Testing
- SA001 Low dose, SA001 Mid dose, SA001 High dose
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Primary Sjögren's Syndrome
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire
- Trial name
- NCT04858464
- Testing
- Survey study
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Gazi University
Primary Sjögren Syndrome
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
This is a first exploration of GLPG3970 in participants with active primary Sjogren's Syndrome (pSS) to evaluate the efficacy, safety and tolerability and to determine its pharmacokinetics (PK) profile compared to placebo.
- Trial name
- GLIDER (NCT04700280)
- Testing
- GLPG3970
- Where
- 10 sites in Germany, Greece and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Primary Sjögren's Syndrome (pSS)
JH013 Injection in Patients With Primary Sjögren's Syndrome
This is a multicenter, open-label, single-arm Phase I study consisting of two parts: Part A, a single-dose dose-escalation phase, and Part B, a multiple-dose dose-escalation phase.
- Trial name
- NCT07818694
- Testing
- JH013 injection
- Volunteers
- 54 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Dry Eye Syndromes, Primary Sjögren Syndrome
LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients
Single-blind, randomised, single centre, 2-way crossover pilot study to investigate the effectiveness of LAMELLEYE for the treatment of dry eye symptoms in patients with primary Sjögren's Syndrome.
- Trial name
- NCT03140111
- Testing
- LAMELLEYE, OPTIVE FUSION
- Volunteers
- 12 people
- Sponsor
- NHS Greater Glasgow and Clyde